A Pilot and Feasibility Study Of The Imaging Potential Of EC17 In Subjects Undergoing Surgery Presenting With Renal Nodules
Phase of Trial: Phase 0
Latest Information Update: 22 Mar 2018
Price : $35 *
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 16 Mar 2018 Status changed from recruiting to completed.
- 04 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Feb 2018, according to ClinicalTrials.gov record.
- 04 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017, according to ClinicalTrials.gov record.